Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Preclinical Pharmacokinetics and Pharmacology Study of RC98: A Programmed Cell Death Ligand 1 Monoclonal Antibody in Cynomolgus Monkeys

Author(s): Ling Wang, Qiaoning Li, Chenglian Deng, Zhihao Liu, Fang Wang, Shenjun Li, Lihou Dong and Jing Jiang*

Volume 30, Issue 16, 2024

Published on: 09 April, 2024

Page: [1240 - 1246] Pages: 7

DOI: 10.2174/0113816128248929230920071937

Price: $65

Abstract

Introduction: RC98 is the monoclonal antibody against Programmed Cell Death Ligand 1 (PD-L1). Relevant reports have confirmed that the influence of PD-L1 expressed by tumor cells on antitumor CD8+ T cell responses is well characterized, but the impact of PD-L1 expressed by immune cells has not been well defined.

Objective: This study aimed to design a Pharmacokinetics/Pharmacology (PK/PD) study of RC98 in normal cynomolgus monkeys to research the effect on the immune system.

Methods: RC98 and vehicle were administered to cynomolgus monkeys at 15 mg/kg via intravenous infusion once a week for 4 weeks to evaluate the relationship between PK and PD. The pharmacodynamic activity was measured by the PD-L1 receptor occupancy (RO) in CD3+ T cells, A T-cell-dependent antibody response (TDAR), and the concentration of soluble PD-L1.

Results: The pharmacokinetic result showed that the exposure from the last administration was lower than that of the first administration, probably due to immunogenicity production. There was a strong correlation between systemic exposure and RO in CD3+ T cells but decreased RO levels after the last dose, which indirectly reflected the activation of T cells. The keyhole limpet hemocyanin (KLH)-induced TDAR in the RC98 group was higher than in the vehicle group. The concentration of soluble PD-L1 had increased feedback with RC98, and the concentration of soluble PD-L1 was maintained at a higher level after multiple doses than before dosing.

Conclusion: These data indicate that the immune system was clearly activated. In addition, the non-clinical data could provide a basis for its efficacy evaluation in clinical trials.

« Previous Next »
[1]
Chen DS, Mellman I. Oncology meets immunology: The cancer-immunity cycle. Immunity 2013; 39(1): 1-10.
[http://dx.doi.org/10.1016/j.immuni.2013.07.012] [PMID: 23890059]
[2]
Li B, Chan HL, Chen P. Immune checkpoint inhibitors: Basics and challenges. Curr Med Chem 2019; 26(17): 3009-25.
[http://dx.doi.org/10.2174/0929867324666170804143706] [PMID: 28782469]
[3]
Sun C, Mezzadra R, Schumacher TN. Regulation and function of the PD-L1 checkpoint. Immunity 2018; 48(3): 434-52.
[http://dx.doi.org/10.1016/j.immuni.2018.03.014] [PMID: 29562194]
[4]
Zuazo M, Arasanz H, Bocanegra A, et al. Systemic CD4 immunity as a key contributor to PD-L1/PD-1 blockade immunotherapy efficacy. Front Immunol 2020; 11: 586907.
[http://dx.doi.org/10.3389/fimmu.2020.586907] [PMID: 33329566]
[5]
Desnoyer A, Broutin S, Delahousse J, et al. Pharmacokinetic/pharmacodynamic relationship of therapeutic monoclonal antibodies used in oncology: Part 2, immune checkpoint inhibitor antibodies. Eur J Cancer 2020; 128: 119-28.
[http://dx.doi.org/10.1016/j.ejca.2020.01.003] [PMID: 32037060]
[6]
Gibbons Johnson RM, Dong H. Functional expression of programmed death-ligand 1 (B7-H1) by immune cells and tumor cells. Front Immunol 2017; 8: 961.
[http://dx.doi.org/10.3389/fimmu.2017.00961] [PMID: 28848559]
[7]
Kythreotou A, Siddique A, Mauri FA, Bower M, Pinato DJ. Pd-L1. J Clin Pathol 2018; 71(3): 189-94.
[http://dx.doi.org/10.1136/jclinpath-2017-204853] [PMID: 29097600]
[8]
Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008; 26(1): 677-704.
[http://dx.doi.org/10.1146/annurev.immunol.26.021607.090331] [PMID: 18173375]
[9]
Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. Nat Med 2002; 8(8): 793-800.
[http://dx.doi.org/10.1038/nm730] [PMID: 12091876]
[10]
Yamazaki T, Akiba H, Iwai H, et al. Expression of programmed death 1 ligands by murine T cells and APC. J Immunol 2002; 169(10): 5538-45.
[http://dx.doi.org/10.4049/jimmunol.169.10.5538] [PMID: 12421930]
[11]
Piccotti JR, Alvey JD, Reindel JF, Guzman RE. T-cell-dependent antibody response: Assay development in cynomolgus monkeys. J Immunotoxicol 2005; 2(4): 191-6.
[http://dx.doi.org/10.1080/15476910500362838] [PMID: 18958673]
[12]
Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366(26): 2443-54.
[http://dx.doi.org/10.1056/NEJMoa1200690] [PMID: 22658127]
[13]
Brahmer JR, Tykodi SS, Chow LQM, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366(26): 2455-65.
[http://dx.doi.org/10.1056/NEJMoa1200694] [PMID: 22658128]
[14]
Dingman R, Balu-Iyer SV. Immunogenicity of protein pharmaceuticals. J Pharm Sci 2019; 108(5): 1637-54.
[http://dx.doi.org/10.1016/j.xphs.2018.12.014] [PMID: 30599169]
[15]
Akinleye A, Rasool Z. Immune checkpoint inhibitors of PD-L1 as cancer therapeutics. J Hematol Oncol 2019; 12(1): 92.
[http://dx.doi.org/10.1186/s13045-019-0779-5] [PMID: 31488176]
[16]
Chang P, Huang L, Huang M, Tian S, Yang Z. Improvement and optimization of a T-cell-dependent antibody response (TDAR) method for BALB/c mice using keyhole limpet hemocyanin (KLH) as specific antigen. J Immunotoxicol 2019; 16(1): 149-54.
[http://dx.doi.org/10.1080/1547691X.2019.1635234] [PMID: 31290717]
[17]
Lebrec H, Molinier B, Boverhof D, et al. The T-cell-dependent antibody response assay in nonclinical studies of pharmaceuticals and chemicals: Study design, data analysis, interpretation. Regul Toxicol Pharmacol 2014; 69(1): 7-21.
[http://dx.doi.org/10.1016/j.yrtph.2014.02.008] [PMID: 24566336]
[18]
Pescovitz MD, Torgerson TR, Ochs HD, et al. Effect of rituximab on human in vivo antibody immune responses. J Allergy Clin Immunol 2011; 128(6): 1295-1302.e5.
[http://dx.doi.org/10.1016/j.jaci.2011.08.008] [PMID: 21908031]
[19]
Ladics GS. Use of SRBC antibody responses for immunotoxicity testing. Methods 2007; 41(1): 9-19.
[http://dx.doi.org/10.1016/j.ymeth.2006.07.020] [PMID: 17161298]
[20]
Jeannin P, Magistrelli G, Aubry JP, et al. Soluble CD86 is a costimulatory molecule for human T lymphocytes. Immunity 2000; 13(3): 303-12.
[http://dx.doi.org/10.1016/S1074-7613(00)00030-3] [PMID: 11021528]
[21]
Oaks MK, Hallett KM. Cutting edge: A soluble form of CTLA-4 in patients with autoimmune thyroid disease. J Immunol 2000; 164(10): 5015-8.
[http://dx.doi.org/10.4049/jimmunol.164.10.5015] [PMID: 10799854]
[22]
Daassi D, Mahoney KM, Freeman GJ. The importance of exosomal PDL1 in tumour immune evasion. Nat Rev Immunol 2020; 20(4): 209-15.
[http://dx.doi.org/10.1038/s41577-019-0264-y] [PMID: 31965064]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy